Fagron（4A5）株式概要ファグロンNVは、病院、薬局、診療所、患者、そして世界中に個別化された医薬品ケアを提供する調剤会社である。 詳細4A5 ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長2/6過去の実績4/6財務の健全性4/6配当金3/6報酬当社が推定した公正価値より68.1%で取引されている 収益は年間13.65%増加すると予測されています 過去5年間の収益は年間9.1%増加しました。 リスク分析多額の負債を抱えている 不安定な配当実績 すべてのリスクチェックを見る4A5 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW495,712 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG495,712 investors already sharing narrativesYour Fair Value€Current Price€23.4516.1% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-25m1b2016201920222025202620282031Revenue €1.5bEarnings €142.7mAdvancedSet Fair ValueView all narrativesFagron NV 競合他社MediosSymbol: XTRA:ILM1Market cap: €297.5mBMP Pharma TradingSymbol: BST:BMPMarket cap: €34.1mRHÖN-KLINIKUMSymbol: XTRA:RHKMarket cap: €903.7mDrägerwerk KGaASymbol: XTRA:DRW3Market cap: €1.5b価格と性能株価の高値、安値、推移の概要Fagron過去の株価現在の株価€23.4552週高値€25.1552週安値€19.40ベータ0.391ヶ月の変化-5.06%3ヶ月変化2.85%1年変化7.82%3年間の変化48.23%5年間の変化34.85%IPOからの変化134.97%最新ニュースお知らせ • May 13Fagron NV Approves Board AppointmentsFagron NV at its Annual and Extraordinary General Meeting of Shareholders held on May 11, 2026 confirmed the final appointments of Ms Ira Bindra as independent director and Mr. Philipp Klecka as non-executive director. Both had previously been appointed by the Board of Directors through co-optation.お知らせ • May 12Fagron NV Approves the Distribution of a Gross Dividend, Payable on 20 May 2026Fagron NV at its Annual and Extraordinary General Meeting of Shareholders held on May 11, 2026 approved the distribution of a gross dividend of EUR 0.40 per share. Ex-dividend date: 18 May 2026. Record date: 19 May 2026. Payment date: 20 May 2026.お知らせ • Feb 27Fagron NV (ENXTBR:FAGR) acquired Pharmavit Europe B.V. for €68 million.Fagron NV (ENXTBR:FAGR) acquired Pharmavit Europe B.V. for €68 million on February 26, 2026. A cash consideration of €68 million will be paid by Fagron NV. As part of consideration, €68 million is paid towards common equity of Pharmavit Europe B.V. For the period ending December 31, 2025, Pharmavit Europe B.V. reported total revenue of €62 million. Fagron NV (ENXTBR:FAGR) completed the acquisition of Pharmavit Europe B.V. on February 26, 2026.お知らせ • Jan 07Fagron NV (ENXTBR:FAGR) completed the acquisition of Gemini Industria De Insumos Farmaceuticos Ltda.Fagron NV (ENXTBR:FAGR) signed an agreement to acquire Gemini Industria De Insumos Farmaceuticos Ltda in a transaction with an enterprise value of BRL 250 million in the third quarter period ending September 30, 2024. The acquisition of Gemini Industria De Insumos Farmaceuticos (Purifarma) marking a significant milestone in cementing Fagron's market position in Brazil. Purifarma operates three facilities and employing around 180 people, Purifarma will integrate into Fagron’s infrastructure, driving synergies through increased operational leverage, procurement savings and an enhanced product portfolio. As of October 6, 2025, The Brazilian competition authority (CADE) approved the acquisition of Purifarma. Completion of the acquisition remains subject to customary closing conditions and completion of certain local corporate and contractual formalities. Augusto Cesar Barbosa de Souza and Leonardo Maniglia Duarte of Veirano Advogados acted as a legal advisor for Fagron NV. Augusto Hirata of Leite de Barros Zanin acted as a legal advisor for Gemini Industria De Insumos Farmaceuticos Ltda. Fagron NV (ENXTBR:FAGR) completed the acquisition of Gemini Industria De Insumos Farmaceuticos Ltda on January 6, 2026.お知らせ • Dec 21Fagron NV (ENXTBR:FAGR) acquired Amber Compounding Pharmacy Pte Ltd.Fagron NV (ENXTBR:FAGR) acquired Amber Compounding Pharmacy Pte Ltd on December 19, 2025. In a related transaction, Fagron NV is acquiring Vepakum. Fagron NV (ENXTBR:FAGR) completed the acquisition of Amber Compounding Pharmacy Pte Ltd on December 19, 2025.お知らせ • Nov 25Fagron NV (ENXTBR:FAGR) acquired Book of business from MAGILAB Korlatolt Felelossegu Tarsasag.Fagron NV (ENXTBR:FAGR) acquired Book of business from MAGILAB Korlatolt Felelossegu Tarsasag on November 24, 2025. In a related transaction, Fagron NV also acquired the book of business of AMARA. The combined purchase price of the two transactions amounts to approximately €26 million. Fagron NV (ENXTBR:FAGR) completed the acquisition of Book of business from MAGILAB Korlatolt Felelossegu Tarsasag on November 24, 2025.最新情報をもっと見るRecent updatesお知らせ • May 13Fagron NV Approves Board AppointmentsFagron NV at its Annual and Extraordinary General Meeting of Shareholders held on May 11, 2026 confirmed the final appointments of Ms Ira Bindra as independent director and Mr. Philipp Klecka as non-executive director. Both had previously been appointed by the Board of Directors through co-optation.お知らせ • May 12Fagron NV Approves the Distribution of a Gross Dividend, Payable on 20 May 2026Fagron NV at its Annual and Extraordinary General Meeting of Shareholders held on May 11, 2026 approved the distribution of a gross dividend of EUR 0.40 per share. Ex-dividend date: 18 May 2026. Record date: 19 May 2026. Payment date: 20 May 2026.お知らせ • Feb 27Fagron NV (ENXTBR:FAGR) acquired Pharmavit Europe B.V. for €68 million.Fagron NV (ENXTBR:FAGR) acquired Pharmavit Europe B.V. for €68 million on February 26, 2026. A cash consideration of €68 million will be paid by Fagron NV. As part of consideration, €68 million is paid towards common equity of Pharmavit Europe B.V. For the period ending December 31, 2025, Pharmavit Europe B.V. reported total revenue of €62 million. Fagron NV (ENXTBR:FAGR) completed the acquisition of Pharmavit Europe B.V. on February 26, 2026.お知らせ • Jan 07Fagron NV (ENXTBR:FAGR) completed the acquisition of Gemini Industria De Insumos Farmaceuticos Ltda.Fagron NV (ENXTBR:FAGR) signed an agreement to acquire Gemini Industria De Insumos Farmaceuticos Ltda in a transaction with an enterprise value of BRL 250 million in the third quarter period ending September 30, 2024. The acquisition of Gemini Industria De Insumos Farmaceuticos (Purifarma) marking a significant milestone in cementing Fagron's market position in Brazil. Purifarma operates three facilities and employing around 180 people, Purifarma will integrate into Fagron’s infrastructure, driving synergies through increased operational leverage, procurement savings and an enhanced product portfolio. As of October 6, 2025, The Brazilian competition authority (CADE) approved the acquisition of Purifarma. Completion of the acquisition remains subject to customary closing conditions and completion of certain local corporate and contractual formalities. Augusto Cesar Barbosa de Souza and Leonardo Maniglia Duarte of Veirano Advogados acted as a legal advisor for Fagron NV. Augusto Hirata of Leite de Barros Zanin acted as a legal advisor for Gemini Industria De Insumos Farmaceuticos Ltda. Fagron NV (ENXTBR:FAGR) completed the acquisition of Gemini Industria De Insumos Farmaceuticos Ltda on January 6, 2026.お知らせ • Dec 21Fagron NV (ENXTBR:FAGR) acquired Amber Compounding Pharmacy Pte Ltd.Fagron NV (ENXTBR:FAGR) acquired Amber Compounding Pharmacy Pte Ltd on December 19, 2025. In a related transaction, Fagron NV is acquiring Vepakum. Fagron NV (ENXTBR:FAGR) completed the acquisition of Amber Compounding Pharmacy Pte Ltd on December 19, 2025.お知らせ • Nov 25Fagron NV (ENXTBR:FAGR) acquired Book of business from MAGILAB Korlatolt Felelossegu Tarsasag.Fagron NV (ENXTBR:FAGR) acquired Book of business from MAGILAB Korlatolt Felelossegu Tarsasag on November 24, 2025. In a related transaction, Fagron NV also acquired the book of business of AMARA. The combined purchase price of the two transactions amounts to approximately €26 million. Fagron NV (ENXTBR:FAGR) completed the acquisition of Book of business from MAGILAB Korlatolt Felelossegu Tarsasag on November 24, 2025.お知らせ • Nov 04Fagron NV, Annual General Meeting, May 11, 2026Fagron NV, Annual General Meeting, May 11, 2026.お知らせ • Oct 10Fagron NV Reaffirms Earnings Guidance for the Fiscal Year 2025Fagron NV reaffirmed earnings guidance for the fiscal year 2025. For the period, Company confirms revenue to be €930 million to €950 million and continue to expect a slight improvement in profitability year on year.お知らせ • Oct 09+ 1 more updateFagron NV to Report Fiscal Year 2025 Results on Feb 12, 2026Fagron NV announced that they will report fiscal year 2025 results on Feb 12, 2026お知らせ • Oct 06Fagron Receives Brazilian Antitrust Clearance for Purifarma and Injeplast AcquisitionsFagron announced that the Brazilian competition authority, CADE, has granted clearance for the previously announced acquisitions of Purifarma and Injeplast in Brazil. The clearances represent an important step forward in executing Fagron’s disciplined M&A strategy in Latin America. The transactions will broaden Fagron’s portfolio and capabilities in Brazil, supporting the Group’s ambition to build a scalable, high-quality platform aligned with its long-term growth objectives.Purifarma operates a highly concentrated Essentials portfolio at very large volumes, presenting significant potential to improve profitability within 18 months post-closing through enhanced product portfolio and brands expansion, as well as increased operational leverage and procurement savings. In addition, the scale-up is expected to generate procurement benefits not only across Latin America but throughout our entire global footprint. Injeplast will further strengthen Fagron’s vertical integration by producing high-quality packaging solutions and efficient manufacturing processes, supporting our Essentials strategy by broadening our product portfolio and customer base in Latin America as well as other regions. Completion of the acquisitions remains subject to customary closing conditions and completion of certain local corporate and contractual formalities.お知らせ • Sep 26Fagron NV (ENXTBR:FAGR) agreed to acquire University Rx Specialists, Inc. at an enterprise value of CAD 41.5 million.Fagron NV (ENXTBR:FAGR) agreed to acquire University Rx Specialists, Inc. at an enterprise value of CAD 41.5 million on September 25, 2025. UCP generates around twenty five million dollars in annual revenue. The transaction will be fully financed through Fagron’s own resources and remains subject to customary clearance.お知らせ • Apr 11Fagron NV (ENXTBR:FAGR) completed the acquisition of Carefirst Specialty Pharmacy LLC.Fagron NV (ENXTBR:FAGR) agreed to acquire Carefirst Specialty Pharmacy LLC on January 7, 2025. In a related transaction, Fagron signed an agreement to acquire Injeplast on January 7, 2025. The combined enterprise value of these two acquisitions is €30 million and are fully financed through Fagron’s own resources and remain subject to customary clearances. Both businesses operate with an EBITDA margin slightly above Fagron’s existing group margin. Fagron NV (ENXTBR:FAGR) completed the acquisition of Carefirst Specialty Pharmacy LLC on April 10, 2025.お知らせ • Feb 22+ 1 more updateFagron NV Provides Earnings Guidance for the Year 2025Fagron NV provided earnings guidance for the year 2025. Full year 2025 outlook of mid- to high-single digit organic sales growth and slight improvement in profitability year on year, at CER and a slight improvement in profitability year-on-year, weighted towards the second half of the year.お知らせ • Feb 05Fagron NV (ENXTBR:FAGR) agreed to acquire Guinama, S.L.U. for an enterprise value of €22 million.Fagron NV (ENXTBR:FAGR) agreed to acquire Guinama, S.L.U. for an enterprise value of €22 million on February 4, 2025. The acquisition will close on signing.お知らせ • Jan 08Fagron NV, Annual General Meeting, May 12, 2025Fagron NV, Annual General Meeting, May 12, 2025.お知らせ • Jan 07+ 4 more updatesFagron NV (ENXTBR:FAGR) agreed to acquire Carefirst Specialty Pharmacy LLC.Fagron NV (ENXTBR:FAGR) agreed to acquire Carefirst Specialty Pharmacy LLC on January 7, 2025. In a related transaction, Fagron signed an agreement to acquire Injeplast on January 7, 2025. The combined enterprise value of these two acquisitions is €30 million and are fully financed through Fagron’s own resources and remain subject to customary clearances. Both businesses operate with an EBITDA margin slightly above Fagron’s existing group margin.お知らせ • Oct 11Fagron NV (ENXTBR:FAGR) ) signed an agreement to acquire Euro OTC Pharma GmbH.Fagron NV (ENXTBR:FAGR) ) signed an agreement to acquire Euro OTC Pharma GmbH in the third quarter period ending September 30, 2024. Acquisition of EuroOTC raw materials will enhance our presence in Germany, creating synergies through increased scale and enhanced customer engagement.お知らせ • Oct 10Fagron NV Reaffirms Earnings Guidance for the Full Year 2024Fagron NV reaffirmed earnings guidance for the full year 2024. Maintain Full Year 2024 revenue outlook of €850 million to €870 million and improvement in profitability year-on-year.Reported Earnings • Aug 05First half 2024 earnings released: EPS: €0.55 (vs €0.45 in 1H 2023)First half 2024 results: EPS: €0.55 (up from €0.45 in 1H 2023). Revenue: €429.3m (up 16% from 1H 2023). Net income: €40.4m (up 22% from 1H 2023). Profit margin: 9.4% (up from 8.9% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Declared Dividend • May 19Dividend of €0.21 announcedShareholders will receive a dividend of €0.21. Ex-date: 21st May 2024 Payment date: 23rd May 2024 Dividend yield will be 1.1%, which is lower than the industry average of 3.3%. Sustainability & Growth Dividend is well covered by both earnings (31% earnings payout ratio) and cash flows (25% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 39% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • May 15Fagron NV Approves Dividend for the Year 2023, Payable on 23 May 2024The annual general meeting approved, amongst other things, Fagron’s annual financial statements and dividend proposal of €0.30 per share for the fiscal year 2023, and the remuneration policy. Ex-dividend date: 21 May 2024. Record date: 22 May 2024. Payment date: 23 May 2024.お知らせ • Apr 11Fagron Provides Earnings Guidance for the Fiscal Year 2024Fagron provided earnings guidance for the fiscal year 2024. For the year, the company expects high single-digit organic sales growth and improvement in profitability reaffirmed.Reported Earnings • Mar 19Full year 2023 earnings released: EPS: €0.97 (vs €0.95 in FY 2022)Full year 2023 results: EPS: €0.97 (up from €0.95 in FY 2022). Revenue: €763.0m (up 12% from FY 2022). Net income: €70.5m (up 1.3% from FY 2022). Profit margin: 9.2% (down from 10% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 18Full year 2023 earnings released: EPS: €0.97 (vs €0.95 in FY 2022)Full year 2023 results: EPS: €0.97 (up from €0.95 in FY 2022). Revenue: €767.2m (up 12% from FY 2022). Net income: €70.5m (up 1.3% from FY 2022). Profit margin: 9.2% (down from 10% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.お知らせ • Feb 16Fagron NV, Annual General Meeting, May 13, 2024Fagron NV, Annual General Meeting, May 13, 2024.お知らせ • Feb 15+ 1 more updateFagron NV Provides Earnings Guidance for the Full Year 2024Fagron NV provided earnings guidance for the full year 2024. For the period, Company expects high single-digit organic revenue growth and continued improvement in profitability.お知らせ • Oct 13Fagron Nv Provides Earnings Guidance for 2023Fagron NV provided earnings guidance for 2023. For full year revenue guidance, The company expects a EUR 750 million to EUR 770 million range. On profitability, the company reiterate guidance of year-on-year increase.お知らせ • Oct 12+ 1 more updateFagron NV to Report First Half, 2024 Results on Aug 01, 2024Fagron NV announced that they will report first half, 2024 results on Aug 01, 2024Reported Earnings • Aug 06First half 2023 earnings released: EPS: €0.45 (vs €0.48 in 1H 2022)First half 2023 results: EPS: €0.45 (down from €0.48 in 1H 2022). Revenue: €371.6m (up 13% from 1H 2022). Net income: €33.0m (down 6.1% from 1H 2022). Profit margin: 8.9% (down from 11% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.お知らせ • May 10+ 1 more updateFagron Nv Announces Board ChangesFagron NV at the annual general meeting of shareholders held on 8 May 2023, approved the stepping down of Management Deprez BV, represented by Veerle Deprez and approved appointment of Els Vandecandelaere LLC, represented by Klaus Röhrig.Reported Earnings • Mar 23Full year 2022 earnings released: EPS: €0.95 (vs €0.84 in FY 2021)Full year 2022 results: EPS: €0.95 (up from €0.84 in FY 2021). Revenue: €683.9m (up 19% from FY 2021). Net income: €69.6m (up 14% from FY 2021). Profit margin: 10% (in line with FY 2021). Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 10Full year 2022 earnings released: EPS: €0.96 (vs €0.84 in FY 2021)Full year 2022 results: EPS: €0.96 (up from €0.84 in FY 2021). Revenue: €683.9m (up 19% from FY 2021). Net income: €70.1m (up 15% from FY 2021). Profit margin: 10% (in line with FY 2021). Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.お知らせ • Feb 09Fagron Nv Proposes DividendFagron NV proposed Dividend of €0.25 per share.お知らせ • Feb 05+ 2 more updatesFagron NV to Report Fiscal Year 2022 Results on Feb 09, 2023Fagron NV announced that they will report fiscal year 2022 results on Feb 09, 2023Board Change • Sep 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Els Vandecandelaere was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 05First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down €26.8m from profit in 1H 2021). Profit margin: (down from 9.7% in 1H 2021). The decrease in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 7.4%, compared to a 2.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Board Change • Jun 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Neeraj Sharma was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 14Full year 2021 earnings released: EPS: €0.84 (vs €0.83 in FY 2020)Full year 2021 results: EPS: €0.84 (up from €0.83 in FY 2020). Revenue: €573.8m (up 3.2% from FY 2020). Net income: €61.0m (up 2.4% from FY 2020). Profit margin: 11% (in line with FY 2020). Over the next year, revenue is forecast to grow 13%, compared to a 4.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 4% per year.Buying Opportunity • Feb 15Now 21% undervaluedOver the last 90 days, the stock is up 9.6%. The fair value is estimated to be €20.44, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.8% per annum over the last 3 years. Earnings per share has grown by 8.0% per annum over the last 3 years.Reported Earnings • Feb 12Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: €0.84 (up from €0.83 in FY 2020). Revenue: €577.9m (up 3.9% from FY 2020). Net income: €61.0m (up 2.4% from FY 2020). Profit margin: 11% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 10%, compared to a 4.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 08First half 2021 earnings released: EPS €0.37 (vs €0.43 in 1H 2020)The company reported a poor first half result with weaker earnings and profit margins, although revenues were flat. First half 2021 results: Revenue: €276.6m (flat on 1H 2020). Net income: €26.9m (down 14% from 1H 2020). Profit margin: 9.7% (down from 11% in 1H 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Jan 04New 90-day low: €18.69The company is down 14% from its price of €21.72 on 06 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €25.91 per share.Is New 90 Day High Low • Sep 28New 90-day high: €21.38The company is up 15% from its price of €18.61 on 30 June 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €24.36 per share.株主還元4A5DE HealthcareDE 市場7D-4.3%-1.2%-2.3%1Y7.8%-2.1%0.3%株主還元を見る業界別リターン: 4A5過去 1 年間で-2.1 % の収益を上げたGerman Healthcare業界を上回りました。リターン対市場: 4A5過去 1 年間で0.3 % の収益を上げたGerman市場を上回りました。価格変動Is 4A5's price volatile compared to industry and market?4A5 volatility4A5 Average Weekly Movement3.3%Healthcare Industry Average Movement5.2%Market Average Movement5.4%10% most volatile stocks in DE Market12.6%10% least volatile stocks in DE Market2.8%安定した株価: 4A5 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 4A5の 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19904,193Rafael Padillawww.fagron.comファグロンNVは医薬品コンパウンド会社で、病院、薬局、診療所、患者、そして世界中に個別化された医薬品ケアを提供している。事業セグメントは3つ：エッセンシャルズ、ブランド、コンパウンドサービス。同社の製品には、あらゆるカプセル製剤を配合するための賦形剤ラインであるDiluCap、免疫反応の調節に役立つImuno TF Complex、白斑などの色素沈着性疾患のための天然植物性複合体であるPigmerise、初回通過代謝を回避し、胃腸浸食を防ぐために使用されるPentravan、傷跡の角ケロイドの予防と治療のための第一選択療法であるNourisil MDなどがある；ヘアケア製品ラインであるネオゲン、脱毛症の治療に使用されるトリココンセプト、基礎的なスキンケア、配合医薬治療、個別の皮膚科治療に使用されるファグロンアドバンスドダーマ、医薬品の安定性、投与量の一貫性、患者の快適性を提供するシルスペンドSF、個別の皮膚科治療の配合に使用される局所クリームであるクレオダーム。また、ファグロンアカデミーを通じて、処方者や薬剤師の教育や専門家育成も行っている。同社は以前Arseus NVとして知られていたが、2015年1月にFagron NVに社名を変更した。Fagron NVは1990年に設立され、ベルギーのナザレを拠点としている。もっと見るFagron NV 基礎のまとめFagron の収益と売上を時価総額と比較するとどうか。4A5 基礎統計学時価総額€1.76b収益（TTM）€91.02m売上高(TTM)€952.17m19.3xPER（株価収益率1.8xP/Sレシオ4A5 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計4A5 損益計算書（TTM）収益€952.17m売上原価€520.16m売上総利益€432.01mその他の費用€340.99m収益€91.02m直近の収益報告Dec 31, 2025次回決算日Jul 30, 2026一株当たり利益（EPS）1.24グロス・マージン45.37%純利益率9.56%有利子負債／自己資本比率74.3%4A5 の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.7%現在の配当利回り32%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/13 11:51終値2026/07/13 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Fagron NV 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13 アナリスト機関Beatrice FairbairnBerenbergSamuel EnglandBerenbergBeatrice AllenBerenberg10 その他のアナリストを表示
お知らせ • May 13Fagron NV Approves Board AppointmentsFagron NV at its Annual and Extraordinary General Meeting of Shareholders held on May 11, 2026 confirmed the final appointments of Ms Ira Bindra as independent director and Mr. Philipp Klecka as non-executive director. Both had previously been appointed by the Board of Directors through co-optation.
お知らせ • May 12Fagron NV Approves the Distribution of a Gross Dividend, Payable on 20 May 2026Fagron NV at its Annual and Extraordinary General Meeting of Shareholders held on May 11, 2026 approved the distribution of a gross dividend of EUR 0.40 per share. Ex-dividend date: 18 May 2026. Record date: 19 May 2026. Payment date: 20 May 2026.
お知らせ • Feb 27Fagron NV (ENXTBR:FAGR) acquired Pharmavit Europe B.V. for €68 million.Fagron NV (ENXTBR:FAGR) acquired Pharmavit Europe B.V. for €68 million on February 26, 2026. A cash consideration of €68 million will be paid by Fagron NV. As part of consideration, €68 million is paid towards common equity of Pharmavit Europe B.V. For the period ending December 31, 2025, Pharmavit Europe B.V. reported total revenue of €62 million. Fagron NV (ENXTBR:FAGR) completed the acquisition of Pharmavit Europe B.V. on February 26, 2026.
お知らせ • Jan 07Fagron NV (ENXTBR:FAGR) completed the acquisition of Gemini Industria De Insumos Farmaceuticos Ltda.Fagron NV (ENXTBR:FAGR) signed an agreement to acquire Gemini Industria De Insumos Farmaceuticos Ltda in a transaction with an enterprise value of BRL 250 million in the third quarter period ending September 30, 2024. The acquisition of Gemini Industria De Insumos Farmaceuticos (Purifarma) marking a significant milestone in cementing Fagron's market position in Brazil. Purifarma operates three facilities and employing around 180 people, Purifarma will integrate into Fagron’s infrastructure, driving synergies through increased operational leverage, procurement savings and an enhanced product portfolio. As of October 6, 2025, The Brazilian competition authority (CADE) approved the acquisition of Purifarma. Completion of the acquisition remains subject to customary closing conditions and completion of certain local corporate and contractual formalities. Augusto Cesar Barbosa de Souza and Leonardo Maniglia Duarte of Veirano Advogados acted as a legal advisor for Fagron NV. Augusto Hirata of Leite de Barros Zanin acted as a legal advisor for Gemini Industria De Insumos Farmaceuticos Ltda. Fagron NV (ENXTBR:FAGR) completed the acquisition of Gemini Industria De Insumos Farmaceuticos Ltda on January 6, 2026.
お知らせ • Dec 21Fagron NV (ENXTBR:FAGR) acquired Amber Compounding Pharmacy Pte Ltd.Fagron NV (ENXTBR:FAGR) acquired Amber Compounding Pharmacy Pte Ltd on December 19, 2025. In a related transaction, Fagron NV is acquiring Vepakum. Fagron NV (ENXTBR:FAGR) completed the acquisition of Amber Compounding Pharmacy Pte Ltd on December 19, 2025.
お知らせ • Nov 25Fagron NV (ENXTBR:FAGR) acquired Book of business from MAGILAB Korlatolt Felelossegu Tarsasag.Fagron NV (ENXTBR:FAGR) acquired Book of business from MAGILAB Korlatolt Felelossegu Tarsasag on November 24, 2025. In a related transaction, Fagron NV also acquired the book of business of AMARA. The combined purchase price of the two transactions amounts to approximately €26 million. Fagron NV (ENXTBR:FAGR) completed the acquisition of Book of business from MAGILAB Korlatolt Felelossegu Tarsasag on November 24, 2025.
お知らせ • May 13Fagron NV Approves Board AppointmentsFagron NV at its Annual and Extraordinary General Meeting of Shareholders held on May 11, 2026 confirmed the final appointments of Ms Ira Bindra as independent director and Mr. Philipp Klecka as non-executive director. Both had previously been appointed by the Board of Directors through co-optation.
お知らせ • May 12Fagron NV Approves the Distribution of a Gross Dividend, Payable on 20 May 2026Fagron NV at its Annual and Extraordinary General Meeting of Shareholders held on May 11, 2026 approved the distribution of a gross dividend of EUR 0.40 per share. Ex-dividend date: 18 May 2026. Record date: 19 May 2026. Payment date: 20 May 2026.
お知らせ • Feb 27Fagron NV (ENXTBR:FAGR) acquired Pharmavit Europe B.V. for €68 million.Fagron NV (ENXTBR:FAGR) acquired Pharmavit Europe B.V. for €68 million on February 26, 2026. A cash consideration of €68 million will be paid by Fagron NV. As part of consideration, €68 million is paid towards common equity of Pharmavit Europe B.V. For the period ending December 31, 2025, Pharmavit Europe B.V. reported total revenue of €62 million. Fagron NV (ENXTBR:FAGR) completed the acquisition of Pharmavit Europe B.V. on February 26, 2026.
お知らせ • Jan 07Fagron NV (ENXTBR:FAGR) completed the acquisition of Gemini Industria De Insumos Farmaceuticos Ltda.Fagron NV (ENXTBR:FAGR) signed an agreement to acquire Gemini Industria De Insumos Farmaceuticos Ltda in a transaction with an enterprise value of BRL 250 million in the third quarter period ending September 30, 2024. The acquisition of Gemini Industria De Insumos Farmaceuticos (Purifarma) marking a significant milestone in cementing Fagron's market position in Brazil. Purifarma operates three facilities and employing around 180 people, Purifarma will integrate into Fagron’s infrastructure, driving synergies through increased operational leverage, procurement savings and an enhanced product portfolio. As of October 6, 2025, The Brazilian competition authority (CADE) approved the acquisition of Purifarma. Completion of the acquisition remains subject to customary closing conditions and completion of certain local corporate and contractual formalities. Augusto Cesar Barbosa de Souza and Leonardo Maniglia Duarte of Veirano Advogados acted as a legal advisor for Fagron NV. Augusto Hirata of Leite de Barros Zanin acted as a legal advisor for Gemini Industria De Insumos Farmaceuticos Ltda. Fagron NV (ENXTBR:FAGR) completed the acquisition of Gemini Industria De Insumos Farmaceuticos Ltda on January 6, 2026.
お知らせ • Dec 21Fagron NV (ENXTBR:FAGR) acquired Amber Compounding Pharmacy Pte Ltd.Fagron NV (ENXTBR:FAGR) acquired Amber Compounding Pharmacy Pte Ltd on December 19, 2025. In a related transaction, Fagron NV is acquiring Vepakum. Fagron NV (ENXTBR:FAGR) completed the acquisition of Amber Compounding Pharmacy Pte Ltd on December 19, 2025.
お知らせ • Nov 25Fagron NV (ENXTBR:FAGR) acquired Book of business from MAGILAB Korlatolt Felelossegu Tarsasag.Fagron NV (ENXTBR:FAGR) acquired Book of business from MAGILAB Korlatolt Felelossegu Tarsasag on November 24, 2025. In a related transaction, Fagron NV also acquired the book of business of AMARA. The combined purchase price of the two transactions amounts to approximately €26 million. Fagron NV (ENXTBR:FAGR) completed the acquisition of Book of business from MAGILAB Korlatolt Felelossegu Tarsasag on November 24, 2025.
お知らせ • Nov 04Fagron NV, Annual General Meeting, May 11, 2026Fagron NV, Annual General Meeting, May 11, 2026.
お知らせ • Oct 10Fagron NV Reaffirms Earnings Guidance for the Fiscal Year 2025Fagron NV reaffirmed earnings guidance for the fiscal year 2025. For the period, Company confirms revenue to be €930 million to €950 million and continue to expect a slight improvement in profitability year on year.
お知らせ • Oct 09+ 1 more updateFagron NV to Report Fiscal Year 2025 Results on Feb 12, 2026Fagron NV announced that they will report fiscal year 2025 results on Feb 12, 2026
お知らせ • Oct 06Fagron Receives Brazilian Antitrust Clearance for Purifarma and Injeplast AcquisitionsFagron announced that the Brazilian competition authority, CADE, has granted clearance for the previously announced acquisitions of Purifarma and Injeplast in Brazil. The clearances represent an important step forward in executing Fagron’s disciplined M&A strategy in Latin America. The transactions will broaden Fagron’s portfolio and capabilities in Brazil, supporting the Group’s ambition to build a scalable, high-quality platform aligned with its long-term growth objectives.Purifarma operates a highly concentrated Essentials portfolio at very large volumes, presenting significant potential to improve profitability within 18 months post-closing through enhanced product portfolio and brands expansion, as well as increased operational leverage and procurement savings. In addition, the scale-up is expected to generate procurement benefits not only across Latin America but throughout our entire global footprint. Injeplast will further strengthen Fagron’s vertical integration by producing high-quality packaging solutions and efficient manufacturing processes, supporting our Essentials strategy by broadening our product portfolio and customer base in Latin America as well as other regions. Completion of the acquisitions remains subject to customary closing conditions and completion of certain local corporate and contractual formalities.
お知らせ • Sep 26Fagron NV (ENXTBR:FAGR) agreed to acquire University Rx Specialists, Inc. at an enterprise value of CAD 41.5 million.Fagron NV (ENXTBR:FAGR) agreed to acquire University Rx Specialists, Inc. at an enterprise value of CAD 41.5 million on September 25, 2025. UCP generates around twenty five million dollars in annual revenue. The transaction will be fully financed through Fagron’s own resources and remains subject to customary clearance.
お知らせ • Apr 11Fagron NV (ENXTBR:FAGR) completed the acquisition of Carefirst Specialty Pharmacy LLC.Fagron NV (ENXTBR:FAGR) agreed to acquire Carefirst Specialty Pharmacy LLC on January 7, 2025. In a related transaction, Fagron signed an agreement to acquire Injeplast on January 7, 2025. The combined enterprise value of these two acquisitions is €30 million and are fully financed through Fagron’s own resources and remain subject to customary clearances. Both businesses operate with an EBITDA margin slightly above Fagron’s existing group margin. Fagron NV (ENXTBR:FAGR) completed the acquisition of Carefirst Specialty Pharmacy LLC on April 10, 2025.
お知らせ • Feb 22+ 1 more updateFagron NV Provides Earnings Guidance for the Year 2025Fagron NV provided earnings guidance for the year 2025. Full year 2025 outlook of mid- to high-single digit organic sales growth and slight improvement in profitability year on year, at CER and a slight improvement in profitability year-on-year, weighted towards the second half of the year.
お知らせ • Feb 05Fagron NV (ENXTBR:FAGR) agreed to acquire Guinama, S.L.U. for an enterprise value of €22 million.Fagron NV (ENXTBR:FAGR) agreed to acquire Guinama, S.L.U. for an enterprise value of €22 million on February 4, 2025. The acquisition will close on signing.
お知らせ • Jan 08Fagron NV, Annual General Meeting, May 12, 2025Fagron NV, Annual General Meeting, May 12, 2025.
お知らせ • Jan 07+ 4 more updatesFagron NV (ENXTBR:FAGR) agreed to acquire Carefirst Specialty Pharmacy LLC.Fagron NV (ENXTBR:FAGR) agreed to acquire Carefirst Specialty Pharmacy LLC on January 7, 2025. In a related transaction, Fagron signed an agreement to acquire Injeplast on January 7, 2025. The combined enterprise value of these two acquisitions is €30 million and are fully financed through Fagron’s own resources and remain subject to customary clearances. Both businesses operate with an EBITDA margin slightly above Fagron’s existing group margin.
お知らせ • Oct 11Fagron NV (ENXTBR:FAGR) ) signed an agreement to acquire Euro OTC Pharma GmbH.Fagron NV (ENXTBR:FAGR) ) signed an agreement to acquire Euro OTC Pharma GmbH in the third quarter period ending September 30, 2024. Acquisition of EuroOTC raw materials will enhance our presence in Germany, creating synergies through increased scale and enhanced customer engagement.
お知らせ • Oct 10Fagron NV Reaffirms Earnings Guidance for the Full Year 2024Fagron NV reaffirmed earnings guidance for the full year 2024. Maintain Full Year 2024 revenue outlook of €850 million to €870 million and improvement in profitability year-on-year.
Reported Earnings • Aug 05First half 2024 earnings released: EPS: €0.55 (vs €0.45 in 1H 2023)First half 2024 results: EPS: €0.55 (up from €0.45 in 1H 2023). Revenue: €429.3m (up 16% from 1H 2023). Net income: €40.4m (up 22% from 1H 2023). Profit margin: 9.4% (up from 8.9% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Declared Dividend • May 19Dividend of €0.21 announcedShareholders will receive a dividend of €0.21. Ex-date: 21st May 2024 Payment date: 23rd May 2024 Dividend yield will be 1.1%, which is lower than the industry average of 3.3%. Sustainability & Growth Dividend is well covered by both earnings (31% earnings payout ratio) and cash flows (25% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 39% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • May 15Fagron NV Approves Dividend for the Year 2023, Payable on 23 May 2024The annual general meeting approved, amongst other things, Fagron’s annual financial statements and dividend proposal of €0.30 per share for the fiscal year 2023, and the remuneration policy. Ex-dividend date: 21 May 2024. Record date: 22 May 2024. Payment date: 23 May 2024.
お知らせ • Apr 11Fagron Provides Earnings Guidance for the Fiscal Year 2024Fagron provided earnings guidance for the fiscal year 2024. For the year, the company expects high single-digit organic sales growth and improvement in profitability reaffirmed.
Reported Earnings • Mar 19Full year 2023 earnings released: EPS: €0.97 (vs €0.95 in FY 2022)Full year 2023 results: EPS: €0.97 (up from €0.95 in FY 2022). Revenue: €763.0m (up 12% from FY 2022). Net income: €70.5m (up 1.3% from FY 2022). Profit margin: 9.2% (down from 10% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 18Full year 2023 earnings released: EPS: €0.97 (vs €0.95 in FY 2022)Full year 2023 results: EPS: €0.97 (up from €0.95 in FY 2022). Revenue: €767.2m (up 12% from FY 2022). Net income: €70.5m (up 1.3% from FY 2022). Profit margin: 9.2% (down from 10% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
お知らせ • Feb 16Fagron NV, Annual General Meeting, May 13, 2024Fagron NV, Annual General Meeting, May 13, 2024.
お知らせ • Feb 15+ 1 more updateFagron NV Provides Earnings Guidance for the Full Year 2024Fagron NV provided earnings guidance for the full year 2024. For the period, Company expects high single-digit organic revenue growth and continued improvement in profitability.
お知らせ • Oct 13Fagron Nv Provides Earnings Guidance for 2023Fagron NV provided earnings guidance for 2023. For full year revenue guidance, The company expects a EUR 750 million to EUR 770 million range. On profitability, the company reiterate guidance of year-on-year increase.
お知らせ • Oct 12+ 1 more updateFagron NV to Report First Half, 2024 Results on Aug 01, 2024Fagron NV announced that they will report first half, 2024 results on Aug 01, 2024
Reported Earnings • Aug 06First half 2023 earnings released: EPS: €0.45 (vs €0.48 in 1H 2022)First half 2023 results: EPS: €0.45 (down from €0.48 in 1H 2022). Revenue: €371.6m (up 13% from 1H 2022). Net income: €33.0m (down 6.1% from 1H 2022). Profit margin: 8.9% (down from 11% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
お知らせ • May 10+ 1 more updateFagron Nv Announces Board ChangesFagron NV at the annual general meeting of shareholders held on 8 May 2023, approved the stepping down of Management Deprez BV, represented by Veerle Deprez and approved appointment of Els Vandecandelaere LLC, represented by Klaus Röhrig.
Reported Earnings • Mar 23Full year 2022 earnings released: EPS: €0.95 (vs €0.84 in FY 2021)Full year 2022 results: EPS: €0.95 (up from €0.84 in FY 2021). Revenue: €683.9m (up 19% from FY 2021). Net income: €69.6m (up 14% from FY 2021). Profit margin: 10% (in line with FY 2021). Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 10Full year 2022 earnings released: EPS: €0.96 (vs €0.84 in FY 2021)Full year 2022 results: EPS: €0.96 (up from €0.84 in FY 2021). Revenue: €683.9m (up 19% from FY 2021). Net income: €70.1m (up 15% from FY 2021). Profit margin: 10% (in line with FY 2021). Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
お知らせ • Feb 05+ 2 more updatesFagron NV to Report Fiscal Year 2022 Results on Feb 09, 2023Fagron NV announced that they will report fiscal year 2022 results on Feb 09, 2023
Board Change • Sep 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Els Vandecandelaere was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 05First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down €26.8m from profit in 1H 2021). Profit margin: (down from 9.7% in 1H 2021). The decrease in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 7.4%, compared to a 2.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Board Change • Jun 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Neeraj Sharma was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 14Full year 2021 earnings released: EPS: €0.84 (vs €0.83 in FY 2020)Full year 2021 results: EPS: €0.84 (up from €0.83 in FY 2020). Revenue: €573.8m (up 3.2% from FY 2020). Net income: €61.0m (up 2.4% from FY 2020). Profit margin: 11% (in line with FY 2020). Over the next year, revenue is forecast to grow 13%, compared to a 4.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 4% per year.
Buying Opportunity • Feb 15Now 21% undervaluedOver the last 90 days, the stock is up 9.6%. The fair value is estimated to be €20.44, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.8% per annum over the last 3 years. Earnings per share has grown by 8.0% per annum over the last 3 years.
Reported Earnings • Feb 12Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: €0.84 (up from €0.83 in FY 2020). Revenue: €577.9m (up 3.9% from FY 2020). Net income: €61.0m (up 2.4% from FY 2020). Profit margin: 11% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 10%, compared to a 4.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 08First half 2021 earnings released: EPS €0.37 (vs €0.43 in 1H 2020)The company reported a poor first half result with weaker earnings and profit margins, although revenues were flat. First half 2021 results: Revenue: €276.6m (flat on 1H 2020). Net income: €26.9m (down 14% from 1H 2020). Profit margin: 9.7% (down from 11% in 1H 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Jan 04New 90-day low: €18.69The company is down 14% from its price of €21.72 on 06 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €25.91 per share.
Is New 90 Day High Low • Sep 28New 90-day high: €21.38The company is up 15% from its price of €18.61 on 30 June 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €24.36 per share.
